TLR7 and systemic lupus erythematosus: Emab inhibits the activation and the expression of PRDM1/Blimp1 in response to BCR and TLR7 stimulation in a subset of CD27−IgD− double-negative (DN) memory B-cells (104), known to be elevated in SLE patients with more active disease (127).